文献速递心脑血管急症

通心络与急性缺血性卒中患者功能结局:一项随机临床试验

Tongxinluo and Functional Outcomes Among Patients With Acute Ischemic Stroke: A Randomized Clinical Trial.
PubMed 文献 · JAMA Netw Open · 2024-09-03
一句话结论急性缺血性卒中72小时内加用通心络口服90天,第90天mRS 0-1分比例65.8% vs 59.1%(OR 1.33,95%CI 1.11-1.60;P=0.002)。

这项多中心、开放标签、双盲随机临床试验纳入2007例入院时NIHSS评分4-22分的急性缺血性卒中患者,在中国50家医院于2014年3月1日至2016年10月31日开展,症状发作72小时内随机分为通心络组或对照组,通心络组口服4粒通心络胶囊、每日3次、共90天,其他治疗按指南进行。改良意向性治疗人群1946例(通心络组973例、对照组973例),第90天通心络组mRS 0-1分比例显著高于对照组(640例[65.8%] vs 575例[59.1%];OR 1.33[95%CI 1.11-1.60];P=0.002)。预设亚组分析显示所有亚组中加用通心络治疗的结局相似。作者认为,在症状发作72小时内的缺血性卒中患者中,加用通心络者较安慰剂组更可能获得良好功能结局,并指出需在溶栓和血管内治疗患者中进一步研究。

要点

  • 症状发作72小时内、入院NIHSS 4-22分的急性缺血性卒中患者,在指南治疗基础上加用通心络口服4粒每日3次共90天,第90天mRS 0-1分比例65.8% vs 59.1%(OR 1.33,95%CI 1.11-1.60;P=0.002)。
  • 通心络组与对照组第90天良好功能结局(mRS 0-1分)绝对差值为6.7个百分点(65.8% vs 59.1%)。
  • 预设亚组分析显示所有亚组中加用通心络治疗的结局相似。
  • 作者指出需在溶栓和血管内治疗患者中进一步研究以探索这些结局。

适用人群与场景

  • 急性缺血性卒中患者,入院时美国国立卫生研究院卒中量表(NIHSS)评分4-22分,症状发作72小时内随机化。
  • 中国50家医院,2014年3月1日至2016年10月31日纳入。

诊断标准与关键阈值

  • 主要结局良好功能结局定义为随机化后第90天改良Rankin量表(mRS)评分0-1分(mRS 0分为无神经功能缺损、无症状或完全恢复,6分为死亡)。
  • 改良意向性治疗人群定义为所有接受随机化、给予任何治疗并接受任何治疗后评估的患者。

处置流程与药物剂量

  • 通心络组口服通心络胶囊4粒,每日3次,共90天;对照组口服安慰剂,方案相同。
  • 其他治疗按指南进行。

研究设计与关键结果

  • 多中心、开放标签、双盲、随机临床试验,纳入2007例急性缺血性卒中患者,中国50家医院,2014年3月1日至2016年10月31日;数据分析时间为2016年11月14日至2017年11月16日。
  • 改良意向性治疗人群1946例(96.5%),通心络组973例、对照组973例,平均(SD)年龄60.5(9.2)岁,男性1342例(69.0%)。
  • 主要终点第90天mRS 0-1分:通心络组640例(65.8%)vs 对照组575例(59.1%);OR 1.33(95%CI 1.11-1.60);P=0.002。
  • 预设亚组分析显示所有亚组中加用通心络治疗的结局相似。

证据类型、等级与局限

  • 证据类型:多中心、开放标签、双盲、随机临床试验。
  • 试验注册号:ClinicalTrials.gov NCT01919671。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在症状发作72小时内的缺血性卒中患者中,加用通心络者较安慰剂组更可能获得良好功能结局。
  • 作者指出需在溶栓和血管内治疗患者中进一步研究以探索这些结局。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Previous studies revealed limited effectiveness of neuroprotective agents in treating acute ischemic stroke (AIS). Tongxinluo, developed from traditional Chinese medicines, has been recognized as a novel neuroprotective agent with anti-inflammatory properties that stabilize vulnerable plaques in animal models and patients with myocardial infarction.

OBJECTIVE: To assess the efficacy and safety of Tongxinluo in patients with acute ischemic stroke (AIS).

DESIGN, SETTING, AND PARTICIPANTS: This multicenter, open-label, double-blind, randomized clinical trial included 2007 patients with AIS and a National Institutes of Health Stroke Scale score between 4 and 22 at admission. The trial was conducted at 50 hospitals in China from March 1, 2014, to October 31, 2016. Data were analyzed from November 14, 2016, to November 16, 2017.

INTERVENTIONS: Eligible patients were randomized within 72 hours of symptom onset to the Tongxinluo group or the control group. Participants received 4 oral capsules of Tongxinluo or placebo, 3 times a day for 90 days. Other treatment was administrated according to guidelines.

MAIN OUTCOMES AND MEASURE: The primary outcome was a favorable functional outcome at day 90 after randomization, defined as a modified Rankin Scale (mRS) score of 0 to 1 (on a scale of 0 [no neurologic deficit, no symptoms, or completely recovered] to 6 [death]). All statistical analyses were performed in a modified intention-to-treat population, defined as all patients who underwent randomization, were given any treatment, and underwent any posttreatment assessment.

RESULTS: Among 2007 patients with AIS who were randomized, 1946 (96.5%) were included in the modified intention-to-treat analysis (973 in the Tongxinluo group and 973 in the control group, with mean [SD] age of 60.5 [9.2] years and 1342 [69.0%] male). Patients in the Tongxinluo group had a significantly higher proportion of favorable functional outcomes at day 90 compared with those in the control group (mRS score of 0-1, 640 [65.8%] vs 575 [59.1%]; odds ratio, 1.33 [95% CI, 1.11-1.60]; P = .002). The prespecified subgroup analyses indicated that, among all subgroups, additional Tongxinluo treatment had similar outcomes.

CONCLUSIONS AND RELEVANCE: Among patients with ischemic stroke within 72 hours after symptom onset, those additionally receiving Tongxinluo were more likely to have a favorable functional outcome, compared with a placebo group. Further research in patients with thrombolysis and endovascular treatment are needed to explore these outcomes.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01919671.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Dong Y, Jiang K, Li Z, et al. Tongxinluo and Functional Outcomes Among Patients With Acute Ischemic Stroke: A Randomized Clinical Trial. JAMA Netw Open. 2024. PMID: 39325453. doi:10.1001/jamanetworkopen.2024.33463

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。